Physician profile
Yi Yang
NPI 1487141792
$16,438.51
in general payments reported to CMS, 2019-2025
22 companies · $4,150 in 2025
The $4,150 reported for 2025 was more than what 88% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $489 · 2023: $8,892 · 2024: $2,908 · 2025: $4,150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,874 · Consulting Fee: $5,375 · Travel and Lodging: $1,223 · Education: $478.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,874.46 |
| Consulting Fee | $5,375.00 |
| Travel and Lodging | $1,222.53 |
| Education | $477.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $7,374.05 | 2022-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $1,345.10 | 2022-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $1,176.15 | 2024-2025 | Tremfya |
| Abbvie INC. | $852.99 | 2022-2025 | Skyrizi, Rinvoq |
| Galderma Laboratories, L.P. | $852.64 | 2023-2025 | Nemluvio |
| Sun Pharmaceutical Industries INC. | $756.94 | 2022-2025 | Winlevi, Absorica Ld, Ilumya |
| Lilly USA, LLC | $628.14 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Ucb, INC. | $576.14 | 2023-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $492.03 | 2023-2025 | |
| Leo Pharma INC. | $407.15 | 2022-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $395.84 | 2022-2025 | |
| Dermavant Sciences, INC. | $337.65 | 2022-2024 | Vtama |
| Pfizer INC. | $319.59 | 2023-2025 | |
| Arcutis Biotherapeutics, INC. | $260.60 | 2023-2025 | Zoryve |
| Amgen INC. | $255.99 | 2022-2025 | Otezla |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $103.77 | 2024-2025 | Cabtreo, Jublia, Siliq |
| E.R. Squibb & Sons, L.L.C. | $86.84 | 2022-2024 | Sotyktu |
| Angiodynamics, INC. | $60.51 | 2023 | Venacure 1470 Pro |
| Merz North America, INC. | $56.40 | 2022-2023 | Xeomin |
| Organon LLC | $53.51 | 2025 | Vtama |
| Biofrontera INC. | $26.54 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Strata Skin Sciences, INC. | $19.94 | 2023 | Xtrac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yi Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.